Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 4, 2015, Pages 810-818

  Hurt, Christopher N ^a   Mukherjee, Somnath ^b   Bridgewater, John ^c   Falk, Stephen ^d   Crosby, Tom ^e   McDonald, Alec ^f   Joseph, George ^e   Staffurth, John ^a   Abrams, Ross A ^g   Blazeby, Jane M ^h   Bridges, Sarah ^a   Dutton, Peter ^b   Griffiths, Gareth ⁱ   Maughan, Tim ^b   Johnson, Colin ⁱ  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e VELINDRE CANCER CENTRE   (United Kingdom)

^f BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DETERIORATION; DISEASES; DRUG PRODUCTS; TOXICITY;

CHEMORADIATION THERAPIES; GASTROINTESTINAL SYMPTOMS; HEALTH-RELATED QUALITY OF LIVES; INDUCTION CHEMOTHERAPY; LOCALLY ADVANCED PANCREATIC CANCERS; NONMETASTATIC CARCINOMA; SIGNIFICANT DETERIORATIONS; STATISTICAL SIGNIFICANCE;

CHEMORADIOTHERAPY;

CAPECITABINE; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADVANCED CANCER; ADVANCED PANCREATIC CANCER; ARTICLE; BLOATING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DISEASE COURSE; DYSPNEA; FATIGUE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INDIGESTION; INDUCTION CHEMOTHERAPY; INSOMNIA; INTENSITY MODULATED RADIATION THERAPY; INTERNAL CONSISTENCY; JAUNDICE; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SEXUAL SATISFACTION; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEEDING AND EATING DISORDERS; FEMALE; GASTROINTESTINAL DISEASES; HEALTH STATUS; MALE; NONPARAMETRIC TEST; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; UNITED KINGDOM; VALIDATION STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEEDING AND EATING DISORDERS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HEALTH STATUS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; SURVEYS AND QUESTIONNAIRES; UNITED KINGDOM;

EID: 84948421502     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.08.026     Document Type: Article

References (12)

1. . Cancer Rese arch UK. Cancer Stats ReportdPancreatic Cancer, vol. 2015. London: Cancer Research UK; 2014.
2. Loehrer PJ Sr,Feng Y,Cardenes H,et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patien ts with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial J Clin Oncol 2011 29, 4105-4112.
3. . Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capeci tabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol 2013;14:317-326.
4. . Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment Of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
5. . Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QOL) questionnaire module to supplement the EORTC core cancer QOL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC study group on quality o f life. Eur J Cancer 1999;35:939-941.
6. . Fayers PM, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 Scoring manual. 3rd ed. Brussels: EORTC Publications; 2001.
7. . Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16: 139-144.
8. . Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill, Inc.; 1994.
9. . Cardenes HR, Powell M, Loehrer PJ, et al. E4201: Randomized phase II study of gemcitabine in combination with radiation therapy versus gemcitabine alone i n patients with locally advanced, unresectable, pancreatic cancer (LAPC): Quality-of-life (qol) analysis. ASCO Meeting Abstracts 2009;27:4627.
10. . Short M, Goldstein D, Halkett G, et al. Impact of gem citabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer. Int J Radiat Oncol Biol Phys 2013;85:157-162.
11. . Serrano PE, H erman JM, Griffith KA, et al. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. In t J Radiat Oncol Biol Phys 2014;90:270-277.
12. . Hammel P, Huguet F, van Laethem JL, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or withou t erlotinib: Final results of the international phase III LAP 07 study. ASCO Meeting Abstracts 2013;31:LBA4003.